PlainPharmaWatch

CMS Open Payments · Tool

Esteve Pharmaceuticals LLC vs Seres Therapeutics, Inc.

Side-by-side comparison of CMS Open Payments data for Program Year 2024. Select different companies below to start a new comparison.

A larger reported total is not "better" or "worse", it is a neutral fact about disclosure volume; a reported payment documents a financial relationship, not evidence of wrongdoing.

Compare Different Companies

vs

Relationship comparison

Which recorded payment profile is more concentrated?

Esteve Pharmaceuticals LLC has the more concentrated recorded General Payments recipient profile in Program Year 2024: its recipient-distribution HHI is 6,597, versus 3,375 for the other company. Its single largest recorded recipient represents 80.2% of that company's General Payments recipient total.

HHI summarizes how payments are distributed across recorded recipients: higher means a less evenly distributed recipient pattern. This is a description of CMS-reported General Payments only, not a finding about conduct, prescribing, quality, or wrongdoing. Read it with the recipient count and underlying records below.

Esteve Pharmaceuticals LLC
HHI 6,597 · top recipient 80.2%
Ranked #240 of 1,838 companies by HHI
Seres Therapeutics, Inc.
HHI 3,375 · top recipient 43.7%
Ranked #520 of 1,838 companies by HHI

Payment Overview

Total Payments
$1.4M
% of Industry
0.0%
Transactions
12
Avg per Transaction
$119.3K
Recipients
8
Avg per Recipient
$179.0K
Payment Types
7
Top Payment Type
Space Rental or Facility Fees
Total Payments
$1.5M
% of Industry
0.0%
Transactions
198
Avg per Transaction
$7.4K
Recipients
42
Avg per Recipient
$34.7K
Payment Types
3
Top Payment Type
Consulting Fee

Highlighted values indicate the higher figure for each metric.

Total payments compared

Esteve Pharmaceuticals LLC vs Seres Therapeutics, Inc. - total reported payments in CMS Open Payments PY2024

Seres Therapeutics, Inc.$1.5MEsteve Pharmaceuticals LLC$1.4M

General Payment Types Breakdown

Category shares use each company's General Payments total, not the all-tracks (General + Research + Ownership) hero figure.

Esteve Pharmaceuticals LLC

Space Rental or Facility Fees $75.0K

80.2%

Travel and Lodging $11.3K

12.1%

Consulting Fee $2.3K

2.4%

Honoraria $1.9K

2.1%

Grant $1.9K

2.1%

Education $979.85

1.0%

Seres Therapeutics, Inc.

Consulting Fee $121.1K

91.4%

Travel and Lodging $10.9K

8.2%

Food and Beverage $476.59

0.4%

Top 5 General-Payment Recipients

This list uses CMS detailed General Payments records only; it excludes research and ownership/investment records, so it does not equal the all-category totals above. A reported payment documents a financial relationship, not evidence of wrongdoing; a higher total reflects reporting volume, not conduct. Verify directly at openpaymentsdata.cms.gov.

Esteve Pharmaceuticals LLC

  1. 1

    Ut Md Anderson Cancer Center

    $75,000.00 · 1 txns

  2. 2

    IRINA BANCOS

    $8,785.25 · 2 txns

  3. 3

    ELIZA GEER

    $7,423.68 · 4 txns

  4. 4

    ANKUR MEHTA

    $2,250.00 · 1 txns

Seres Therapeutics, Inc.

  1. 1

    Willard Dere

    $57,820.55 · 21 txns

  2. 2

    Dennis Ausiello

    $37,500.00 · 3 txns

  3. 3

    Timothy Leach

    $34,200.00 · 8 txns

  4. 4

    ELIZABETH GHERA

    $1,080.00 · 1 txns

  5. 5

    RANDY TAPLITZ

    $800.00 · 2 txns

Summary Comparison

Metric Esteve Pharmaceuticals LLC Seres Therapeutics, Inc.
Total Payments $1.4M $1.5M
% of Industry Total 0.0% 0.0%
Transaction Count 12 198
Avg per Transaction $119.3K $7.4K
Recipient Count 8 42
Avg per Recipient $179.0K $34.7K
Payment Type Count 7 3
Top Payment Type Space Rental or Facility Fees Consulting Fee

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. All companies in the CMS Open Payments company corpus are available in the selector. Browse all companies →

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.